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Abstract
Background:  Genome-wide association studies have identified numerous single nucleotide
polymorphisms (SNPs) affecting high density lipoprotein (HDL) or low density lipoprotein (LDL)
cholesterol levels; these SNPs may contribute to the genetic basis of vascular diseases.
Results: We assessed the impact of 34 SNPs at 23 loci on dyslipidemia, key lipid sub-phenotypes,
and severe carotid artery disease (CAAD) in a case-control cohort. The effects of these SNPs on
HDL and LDL were consistent with those previously reported, and we provide unbiased estimates
of the percent variance in HDL (3.9%) and LDL (3.3%) explained by genetic risk scores. We
assessed the effects of these SNPs on HDL subfractions, apolipoprotein A-1, LDL buoyancy,
apolipoprotein B, and lipoprotein (a) and found that rs646776 predicts apolipoprotein B level while
rs2075650 predicts LDL buoyancy. Finally, we tested the role of these SNPs in conferring risk for
ultrasonographically documented CAAD stenosis status. We found that two loci, chromosome
1p13.3 near CELSR2 and PSRC1 which contains rs646776, and 19q13.2 near TOMM40 and APOE
which contains rs2075650, harbor risk alleles for CAAD.
Conclusion: Our analysis of 34 SNPs contributing to dyslipidemia at 23 loci suggests that genetic
variation in the 1p13.3 region may increase risk of CAAD by increasing LDL particle number,
whereas variation in the 19q13.2 region may increase CAAD risk by promoting formation of
smaller, denser LDL particles.
Background
Carotid artery disease (CAAD) is an important risk factor
for stroke, the third leading cause of death in the U.S.
Given the high mortality, morbidity, and economic costs
due to stroke, primary prevention, particularly targeted
toward high risk individuals, is the most promising
approach to combat stroke[1,2]. Although medical inter-
ventions and carotid endarterectomy can potentially pre-
vent strokes in individuals with CAAD, routine screening
is not currently recommended[1]. However, it has been
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suggested that if high risk groups with CAAD prevalences
of approximately 20% can be identified, screening may
provide significant and cost effective extension to quality
adjusted life years[3,4]. Studies of siblings[5,6],
twins[7,8], and families[9] suggest a heritable genetic con-
tribution to carotid artery intima-media thickening and
stenosis from plaque, with the heritability of ultrasono-
graphically measured phenotypes typically ranging from
20% to 40% in population based samples[10]. Thus,
identification of genetic risk factors for carotid artery sten-
osis, progression, and plaque instability may ultimately
be useful in targeting primary prevention against stroke in
patients for whom management strategies are not yet well
defined.
Recently a number of large genome-wide association stud-
ies have revealed loci affecting total cholesterol, high-den-
sity lipoprotein cholesterol (HDL), low-density
lipoprotein cholesterol (LDL), and triglycerides [11-15].
Because of their role in promoting dyslipidemia, these
single nucleotide polymorphisms (SNPs) are strong can-
didates for contributing to genetic risk for atherosclerosis,
and several studies have found significant impacts of these
loci on coronary artery disease[11,12,16]. Although many
clinical risk factors such as age, smoking, hypertension,
and diabetes are shared between CAAD and coronary
artery disease, the relative importance of these risk factors
differs between these two vascular disease processes [17].
Similarly, the relative importance of risk factors varies for
disease at different locations within the carotid arteries
themselves[9,10]. These discrepancies suggest that addi-
tional factors, including genetic ones, may modulate the
atherosclerotic disease process differently in different ana-
tomic locations. Thus, the impact of recently discovered
dyslipidemia risk alleles on CAAD is as yet unknown.
Based on previous success in applying genetic risk scores
for decreased HDL and increased LDL to the prediction of
coronary artery disease[12] and the central role of these
lipid fractions in evidence-based guidelines for coronary
artery disease risk reduction[18], we investigated the role
of SNPs affecting HDL and LDL in predicting risk for
CAAD. We also sought to determine whether these SNPs
alter key lipid sub-phenotypes with differential athero-
genic potential. Specifically, the more efficient cholesterol
efflux activity of apolipoprotein A-I (apo A-I) [19] has
lead to the hypothesis that the HDL2 subfraction or apo A-
I may be a better predictor of protection against athero-
sclerosis than HDL3 or total HDL. We also tested SNPs for
their effects on apolipoprotein B (apo B), which measures
LDL particle number and may be a better estimator of car-
diovascular disease risk than LDL level[20,21], LDL buoy-
ancy which predicts the smaller, denser LDL pattern B
phenotype [22] associated with increased risk of coronary
artery disease[23], and lipoprotein(a) (Lp(a)) which
appears to independently predict risk of coronary artery
disease [24] and stroke [25]. These analyses may suggest
mechanisms through which specific SNPs modulate
CAAD risk beyond their effects on HDL and LDL levels.
Results
Effects of SNPs on HDL and LDL
As shown in Figure 1 our data confirm the previously
reported effects on HDL and LDL for the majority of SNPs
tested in CLEAR study participants (see Table 1). Out of
34 SNPs tested (see Table 2), we identified 14 SNPs that
showed nominally significant associations with HDL or
LDL levels at a p-value of 0.05, corresponding to a FDR of
0.11 when corrected for multiple testing. These 14 SNPs
correspond to those for which the 95% confidence inter-
vals do not cross zero in Figure 1. For only three SNPs the
95% confidence intervals do not contain the previously
reported effect from the literature, and for the top 25
SNPs, those indicated by closed circles, our data are more
likely assuming the effect as reported in the literature (i.e.
's as given by the x's in Figure 1) than under the null (
= 0). Furthermore, for 28 out of 34 SNPs the effects on
ˆ β ˆ β
Table 1: Characteristics of CLEAR participants.
Controls ≤15% stenosis
(N, 25th/50th/75th percentiles, or %)
50-79% stenosis Cases ≥80% stenosis P-valuea
N4 7 9 8 3 3 5 3
Censored age 60/66/72 66/71/76 59/66/72 0.30
Current smoker 9.5% 18% 33% 2.1 × 10-16
Pack-years smoked 0.0/5.2/30 8.8/32/68 15/45/69 6.1 × 10-36
Body mass index (BMI) 25/28/31 24/27/30 24/27/30 0.0025
Anti-hypertensive medication use 49% 86% 84% 5.9 × 10-25
Diabetes 18% 29% 34% 4.8 × 10-8
Lipid lowering medication use 22% 69% 68% 7.9 × 10-40
HDL (mg/dL) 39/47/57 35/40/50 35/41/49 5.2 × 10-11
LDL (mg/dL) 97/115/134 86/102/126 86/102/125 1.3 × 10-5
aP-values are derived from t-tests for the difference in means or χ2 tests for the difference in percentages between controls (≤15% stenosis) and 
cases (≥80% stenosis).Lipids in Health and Disease 2009, 8:52 http://www.lipidworld.com/content/8/1/52
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Table 2: SNPs analyzed in the CLEAR study.
SNP Chr Base Pair Nearby Gene(s) Minor (Major) Allele Change in HDL/LDL per 
copy of minor allele (mg/dL)
Genotyped/Imputation 
Accuracyf
rs11206510ab 1 55268627 PCSK9 C (T) -2.8 LDL 0.55
rs11591147cd 1 55278235 PCSK9 T (G) -16.4 LDL Genotyped
rs12740374a 1 109619113 CELSR2-PSRC1-SORT1 T (G) -7.1 LDL 0.97g
rs646776de 1 109620053 CELSR2-PSRC1-SORT1 G (A) -4.8 LDL Genotyped
rs4846914ad 1 228362314 GALNT2 G (A) -0.7 HDL Genotyped
rs6754295e 2 21059688 APOB C (A) 0.9 HDL Genotyped
rs693bcde 2 21085700 APOB G (A) -3.0 LDL Genotyped
rs7575840c 2 21126995 APOB T (G) 3.7 LDL Genotyped
rs515135a 2 21139562 APOB T (C) -4.9 LDL 0.90
rs6756629e 2 43918594 ABCG5 A (G) -4.8 LDL Genotyped
rs6544713a 2 43927385 ABCG8 T (C) 4.6 LDL 1.00
rs12654264cd 5 74684359 HMGCR T (A) 2.7 LDL Genotyped
rs3846662e 5 74686840 HMGCR G (A) 2.4 LDL Genotyped
rs3846663a 5 74691482 HMGCR T (C) 2.1 LDL 0.97h
rs1501908a 5 156330747 TIMD4-HAVCR1 G (C) -2.1 LDL 0.11
rs12670798c 7 21573877 DNAH11 G (A) 2.7 LDL 0.18
rs328cd 8 19864004 LPL G (C) 2.9 HDL Genotyped
rs10096633e 8 19875201 LPL A (G) 1.9 HDL 0.94i
rs12678919a 8 19888502 LPL G (A) 3.2 HDL 0.94i
rs2083637e 8 19909455 LPL G (A) 1.5 HDL 0.45
rs471364a 9 15279578 TCC39B C (T) -1.1 HDL No genotyped SNPs within 
200 kb
rs3890182cd 9 106687476 ABCA1 A (G) -1.1 HDL Genotyped
rs3905000e 9 106696891 ABCA1 A (G) -1.6 HDL 0.98j
rs1883025a 9 106704122 ABCA1 T (C) -1.1 HDL Genotyped
rs7395662e 11 48475469 MADD-FOLH1 A (G) 1.0 HDL No genotyped SNPs within 
200 kb
rs174547a 11 61327359 FADS1-FADS2-FADS3 C (T) -1.2 HDL 1.00
rs174570e 11 61353788 FADS1-FADS2-FADS3 A (G) -3.4 LDL Genotyped
rs964184a 11 116154127 APOA1-APOC3-APOA4-
APOA5
G (C) -2.3 HDL 1.00
rs2338104ab 12 108379551 MMAB-MVK C (G) -1.0 HDL Genotyped
rs2650000a 12 119873345 HNF1A A (C) 2.1 LDL 0.98
rs10468017a 15 56465804 LIPC T (C) 1.4 HDL 0.029
rs1532085e 15 56470658 LIPC A (G) 1.8 HDL 0.17
rs1800588cd 15 56510967 LIPC T (C) 1.4 HDL Genotyped
rs173539a 16 55545545 CETP T (C) 3.4 HDL 1.00
rs1800775cd 16 55552737 CETP A (C) 2.5 HDL Genotyped
rs1532624e 16 55562980 CETP A (C) 2.9 HDL Genotyped
rs2271293ae 16 66459571 LCAT-CTCF-PRMT8 A (G) 1.8 HDL 0.98
rs4939883ae 18 45421212 LIPG A (G) -1.4 HDL 0.92
rs2967605a 19 8375738 ANGPTL4 T (C) -1.6 HDL 0.76
rs1529729c 19 11024562 LDLR C (T) 1.9 LDL Genotyped
rs6511720abc 19 11063306 LDLR T (G) -4.6 LDL Genotyped
rs2228671e 19 11071912 LDLR A (G) -4.2 LDL Genotyped
rs688c 19 11227602 LDLR T (C) 1.4 LDL Genotyped
rs10401969a 19 19268718 NCAN-CILP2-PBX4 C (T) -1.5 LDL 0.22
rs16996148bd 19 19519472 NCAN-CILP2-PBX4 T (G) -3.1 LDL Genotyped
rs157580e 19 50087106 TOMM40-APOE G (A) -3.4 LDL Genotyped
rs2075650e 19 50087459 TOMM40-APOE G (A) 4.9 LDL Genotyped
rs4420638abc 19 50114786 APOE G (A) 8.9 LDL 0.81
rs6102059a 20 38662198 MAFB T (C) -1.8 LDL -0.074
rs1800961a 20 42475778 HNF4A T (C) -2.6 HDL Genotyped
rs7679a 20 44009909 PLTP C (T) -1.0 HDL Genotyped
The estimated changes in HDL or LDL per copy of the minor allele are based on effects reported in aKathiresan et al[14], bWiller CJ et al[15], cKathiresan et al[12], 
dKathiresan et al[13], and eAulchenko et al[11]. fOnly SNPs with estimated imputation accuracies of >90% were included in downstream analyses. gExcluded from 
downstream analyses due to r2 = 1.00 with rs646776. hExcluded due to r2 = 0.99 with rs12654264. iExcluded due to r2 = 0.93 and 0.95 with rs328. jExcluded due to r2 = 0.96 
with rs3890182.Lipids in Health and Disease 2009, 8:52 http://www.lipidworld.com/content/8/1/52
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HDL or LDL in our data were in the same direction as
reported previously in the literature, corresponding to sig-
nificant concordance under a binomial test (p = 2.0 × 10-
4).
Given the small marginal effects of the recently reported
SNPs on HDL or LDL levels, we used a genetic risk score
combining alleles additively across SNPs to better predict
lipid levels. Such genetic risk scores have previously been
utilized, but they are subject to upward bias when devel-
oped in the same sample used to initially detect associa-
tions. Using a risk score with SNPs weighted by the
reported effect sizes from the literature (see Table 2) and
after accounting for covariates, the 16 HDL SNPs explain
3.9% of the variation in HDL levels (p = 4.3 × 10-9). Using
the same approach, the 18 LDL SNPs explain 3.3% of the
variation in LDL levels (p = 4.4 × 10-8).
Effects of SNPs on lipid sub-phenotypes
With few exceptions we found that the same SNPs signifi-
cantly associated with total HDL in our data were also
associated with HDL2, HDL3, and apo A-I. At a p-value of
0.05, corresponding to an FDR of 0.11, we identified 19
significant associations between the 16 HDL SNPs and
HDL2, HDL3, or apo A-I. In a principal component analy-
sis of the t-statistics derived from tests of association
between the 16 HDL SNPs and 4 phenotypes (total HDL,
HDL2, HDL3, and apo A-I), we found that the first princi-
pal component was positively correlated with all 4 pheno-
types and explained 94% of the variance in the t-statistics,
indicating that the effects of each SNP were highly con-
cordant across all HDL related phenotypes. Similarly, the
hierarchical clustering analysis performed by Kathiresan
et al[14] also shows that the current set of genetic loci
affecting HDL does little to discriminate among HDL2,
HDL3, and apo A-I levels.
At a p-value of 0.05, we found that rs646776, rs693,
rs2228671, and rs6511720 were associated with apo B
and that rs2075650 and rs2650000 were associated with
LDL buoyancy. The associated FDR for these tests was
quite high at 0.35, due in part to the absence of any affect
of these SNPs on Lp(a). Among SNPs associated with apo
B, rs646776 was by far the most statistically significant (p
= 0.00035, compared with 0.017 ≤ p < 0.05 for the
remaining three) with its minor allele decreasing apo B
(  = -3.3). Kathiresan et al[14] found a similarly strong
effect on apo B of the nearby SNP rs12740374 (  = -3.3;
p = 1.2 × 10-8), which is nearly perfectly correlated with
rs646776 (see Table 2). Among SNPs associated with LDL
buoyancy, rs2075650 was the most statistically significant
(p = 0.014), with the minor allele decreasing the relative
flotation rate (  = -0.0047) leading to a more athero-
genic phenotype.
Effects of SNPs on CAAD risk
After a Bonferroni correction for 34 tests, corresponding
to a threshold of p = 0.0015, Figure 2 shows that two
SNPs, rs646776 and rs2075650, met criteria for signifi-
cant association with CAAD. For convenience SNPs have
been recoded from minor allele dose to unfavorable allele
dose based on their effect on HDL or LDL so that the
expected effect on CAAD is   >0. Due to the prior expec-
tation that alleles that decrease HDL or increase LDL
would confer increased risk for CAAD, we performed one-
sided tests. The major allele of rs646776 is associated with
increased LDL, increased apo B as described above, and
increased risk of CAAD (  = 0.47; p = 0.0012). The
minor allele of rs2075650 is associated with increased
LDL, decreased LDL buoyancy as described above, and
increased risk of CAAD (  = 0.56; p = 0.00091). Results
were similar when we analyzed percent carotid stenosis
(with controls, individuals with intermediate stenosis,
and cases having phenotypes coded 0, 0.5, and 0.8 respec-
tively) in a linear regression allowing for inclusion of 83
additional individuals with intermediate carotid stenosis
with luminal narrowing of 50 to 79% (p = 0.0049 for
rs646776, p = 0.0010 for rs2075650).
The associations between rs646776 and rs2075650 and
CAAD could not be explained by their effects on HDL and
LDL levels alone. We found that including the observed
HDL and LDL levels, use of lipid lowering therapy, or
"pre-therapy" HDL and LDL levels (see Methods) as cov-
ariates did not dramatically change the significance or
magnitude of the associations between CAAD and
rs646776 or rs2075650 (data not shown). Combined
with their effects on LDL particle number and buoyancy,
these results raise the possibility that rs646776 and
rs2075650 contribute additional information to current
HDL and LDL levels alone for CAAD risk prediction.
Genetic risk score for CAAD
Contrary to HDL and LDL, we did not find that CAAD risk
prediction was improved using an additive risk score
based on these SNPs. We tested both a risk score in which
all SNPs were weighted equally as in Kathiresan et al[12]
(p = 0.32), and one in which SNPs were weighted by the
magnitude of their effects on HDL and LDL as in
Aulchenko et al[11] (p = 0.63). Results were similar with
or without HDL, LDL, and use of lipid lowering as covari-
ates. To clarify this finding, we sought to determine our
power to detect association between the genetic risk score
ˆ β
ˆ β
ˆ β
ˆ β
ˆ β
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and CAAD, given that the risk score based on these SNPs
explains only 3.9% and 3.3% of the variance in HDL and
LDL levels, respectively, and given that dyslipidemia is
only one of several risk factors for CAAD. Using power
simulations (see Methods), we found that the genetic risk
score, acting through its effects on HDL and LDL levels
alone, had an expected odds ratio for association with
CAAD of 1.03 to 1.04 per unfavorable allele. The power
based on these effect sizes was only 20% to 39%, suggest-
ing that we cannot reject a model in which the overall
genetic score confers risk of CAAD, but mainly through its
effect on lipid levels. However, if the odds ratio per unfa-
vorable allele averaged as little as 1.07 to 1.10 our power
to detect association between the risk score and CAAD was
81% to 97%. This suggests that if a significant fraction of
these 34 SNPs are predictive of CAAD risk beyond their
effects on measured HDL and LDL levels, we would have
had high power to detect such an association.
CAAD risk locus on chromosome 1p13.3
To further explore the CAAD association in the vicinity of
rs646776 we analyzed 82 additional SNPs that were gen-
otyped or imputed with at least 80% accuracy, and Figure
3 shows that rs646776 and neighboring SNPs in CELSR2
and PSRC1 exhibit the greatest statistical significance. To
correct for multiple testing in the setting of strong linkage
disequilibrium we performed permutation testing to esti-
mate a significance threshold of p = 0.0040. Within
SORT1 the intronic SNP rs4970843 shows significant
association (p = 0.0030). Interestingly rs4970843 is in
weak but significant long range linkage disequilibrium
with rs646776 (r2 = 0.083; p = 2.5 × 10-19), and is in rela-
tively weaker linkage disequilibrium with nearby SNPs in
the highly correlated block encompassing SORT1.
Effects of SNPs on HDL and LDL Figure 1
Effects of SNPs on HDL and LDL. The estimated regression coefficient (circles) for the effect of each SNP on HDL or LDL 
(listed on the right) is shown with the associated 95% confidence interval. Previously reported effects from the literature are 
marked with x's. SNPs are sorted by decreasing relative likelihood under the alternative (  as given by the x) versus the null 
hypothesis (  = 0) with closed circles indicating SNPs for which the data are more likely under the alternative hypothesis.
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CAAD risk locus on chromosome 19p13.2
Figure 4 shows that rs2075650, an intronic SNP in
TOMM40, displays stronger association with CAAD than
rs429358, which defines the ε3/ε4 dichotomy, or rs7412,
which defines the ε2/ε3 dichotomy, in the APOE ε2/ε3/ε4
polymorphism. When rs2075650 and rs429358 were ana-
lyzed conditional on one another, we found significant
association with rs2075650 (p = 0.032) but not with
rs429358 (p = 0.61). This did not appear to be due to the
additive model being a poor fit for the effect of APOE,
because when we utilized a two degree of freedom model
for the ε3/ε4 effect, rs2075650 retained significance (p =
0.031) whereas neither the recessive nor dominance term
for rs429358 was significant (p = 0.78 and p = 0.72,
respectively). When rs2075650 and rs7412 were analyzed
conditional on one another we found that both showed
significant association with CAAD (p = 0.0047 for
rs2075650 and p = 0.012 for rs7412). With a two degree
of freedom model, rs2075650 retained significance (p =
0.0046) while the dominance term (p = 0.021) but not
the recessive term (p = 0.40) was significant for rs7412.
When all three SNPs were analyzed simultaneously
including an interaction term for ε2/ε3 with ε3/ε4,
rs2075650 was suggestively significant (p = 0.055), nei-
ther rs429358 nor its interaction with rs7412 was signifi-
cant (p = 0.63 and p = 1.00, respectively), and rs7412 was
significant (p = 0.036).
Discussion
Our data confirm the effects of recently identified dyslipi-
demia SNPs, and we estimated that, after accounting for
other covariates, genetic risk scores explain 3.9% and
3.3% of the variance in HDL and LDL, respectively.
Although slightly different sets of SNPs and weighting fac-
tors were used, these values are in reasonable agreement
with those of 4.8% and 3.4% as reported by Aulchenko et
al[11]. Our estimates may be biased lower because of the
extensive use of lipid lowering therapy in CLEAR partici-
Effects of SNPs on CAAD risk Figure 2
Effects of SNPs on CAAD risk. The estimated coefficient (circles) for each SNP in a logistic regression model of CAAD 
case versus control status is shown along with the associated 95% (longer vertical ticks) and 99.9% (shorter vertical ticks) con-
fidence intervals, corresponding to one-sided p-values of 0.05 and 0.0015 respectively. Closed circles with confidence intervals 
in solid lines represent those SNPs that are significantly associated with CAAD after a Bonferroni correction for 34 tests.
β (CAAD case status versus unfavorable allele dose)
−2 −1 0 1 2
rs157580
rs7679
rs174570
rs4846914
rs6544713
rs4939883
rs2075650
rs6754295
rs16996148
rs3890182
rs2650000
rs174547
rs2271293
rs11591147
rs515135
rs1529729
rs1800961
rs1800588
rs2338104
rs7575840
rs688
rs12654264
rs1883025
rs6756629
rs6511720
rs964184
rs328
rs2228671
rs3846662
rs693
rs1532624
rs646776
rs173539
rs1800775Lipids in Health and Disease 2009, 8:52 http://www.lipidworld.com/content/8/1/52
Page 7 of 12
(page number not for citation purposes)
pants with various pharmacological agents, dosing, and
medication compliance which we have not attempted to
fully model. In addition, while Aulchenko et al. sought to
reduce upward bias by estimating weights for each SNP in
independent cohorts from that in which the risk score was
applied, the fact that the set of SNPs used in the risk score
was apparently identified using all available cohorts sug-
gests that a slight upward bias would still remain in their
estimates. Based on the estimated effect sizes of this panel
of SNPs on HDL and LDL, and the estimated effect size of
dyslipidemia on CAAD, our data cannot exclude a model
in which these SNPs as a group increase risk of CAAD
mostly or entirely through their effects on lipids. How-
ever, our failure to identify a significant association
between an overall risk score based on these SNPs and
CAAD suggests that the majority of these SNPs are
unlikely to contribute strongly to CAAD beyond their role
in promoting dyslipidemia.
This result highlights a potential cause for caution in using
a genetic risk score derived from an intermediate pheno-
type to predict disease. If genetic variants contributing to
such a score act only through the intermediate clinical var-
iable, then use of the clinical variable is likely to be supe-
rior. On the other hand, if genetic variants contribute to
disease risk in ways not captured by the clinical variable,
for example because they provide an index of lifetime
exposure or because of pleiotropy with effects on the dis-
ease through multiple pathways, then a risk score may
have significant clinical utility. However, when a score for
Linkage disequilibrium structure and association results for the chromosome 1p13.3 region containing rs646776 Figure 3
Linkage disequilibrium structure and association results for the chromosome 1p13.3 region containing 
rs646776. The lower portion of the figure shows pairwise linkage disequilibrium in HapMap individuals with white indicating r2 
= 0 and black indicating r2 = 1. Approximate boundaries of linkage disequilibrium blocks are traced. The locations of genotyped 
and imputed SNPs relative to the genes in the region (middle portion) are shown with black and light gray lines, respectively. 
Exonic regions of genes are shaded dark gray. The upper portion shows -log10 p-values for association with CAAD, with nom-
inal significance (p = 0.05) and permutation corrected significance levels for 83 analyzed SNPs indicated by the lower and upper 
dashed lines, respectively. rs646776, rs599839, and rs4970843 are marked by the open triangle, square, and circle, respectively.
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an intermediate phenotype is developed using tens or
hundreds of SNPs, it is likely that only a subset of the con-
tributing SNPs will have these favorable predictive prop-
erties. Within the context of our study, we found no
significant predictive power of the overall dyslipidemia
risk score beyond what would be predicted by the role of
dyslipidemia in CAAD alone, yet we identify two SNPs,
rs646776 and rs2075650, which appear to mediate risk
for CAAD beyond their effects on HDL and LDL. Based on
its association with apo B, our analyses indicate that
rs646776 affects LDL particle number in addition to LDL
level, which may account for the additional explanatory
power of this SNP. In contrast, rs2075650 appears to
affect LDL buoyancy, with the minor allele contributing to
the smaller, denser LDL particles that make up the more
atherogenic LDL pattern B phenotype.
Based on our analyses of the 1p13.3 region containing
rs646776, variation associated with CAAD is most likely
located near CELSR2, a non-classical cadherin that does
not interact with catenins, or PSRC1, a p53-regulated
growth receptor. Although SORT1, a multi-ligand receptor
present in the Golgi and on the cell surface, represents a
good candidate gene because it binds and mediates degra-
dation of lipoprotein lipase [26], increases its localization
to the plasma membrane of adipocytes in response to
insulin, and forms GLUT4 storage vesicles which enhance
insulin sensitivity [27], our association signal was weaker
in this gene. Given the strong linkage disequilibrium
according to HapMap data, it is unlikely that there exists
common variation in SORT1 that was not captured by our
study. Although the 1p13.3 region appears to show robust
association with coronary artery disease [28-30], a recent
study that included 33,282 participants with a total of 503
strokes at baseline and 571 incident strokes did not iden-
tify a significant association between stroke and either
rs599839 or rs4970834 in this region[31]. However,
stroke is the sequela of a diverse set of underlying patho-
Linkage disequilibrium structure and association results for the chromosome 19p13.2 region containing rs2075650 Figure 4
Linkage disequilibrium structure and association results for the chromosome 19p13.2 region containing 
rs2075650. See the Figure 3 caption for further description. The upper dashed line represents a Bonferroni correction for 25 
analyzed SNPs. rs2075650, rs429358, and rs7412 are indicated by the open triangle, square, and circle, respectively.
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physiologic causes which do not appear to have been dis-
tinguished in this study[32], so it is unclear whether this
sample size would have sufficient power to detect an affect
of the 1p13.3 region on the subset of strokes due to
CAAD.
In the 19p13.2 region APOE is a stronger candidate gene
than TOMM40, a channel forming subunit that is essen-
tial for protein import into the mitochondria [33]. The ε2/
ε3/ε4 polymorphism is reported to be a equivocal risk fac-
tor for carotid atherosclerosis[10] although a more recent
meta-analysis does support a modest association between
these SNPs and carotid intima media thickness [34]. Con-
sistent with this, our data show nominally significant pro-
tective effects of the ε2 allele and deleterious effects of the
ε4 allele. However, conditioning on these SNPs did not
account for the CAAD association signal in the region, and
moreover the ε4 allele failed to demonstrate significant
association with CAAD when rs2075650 was jointly con-
sidered. This result argues against a singular causal role for
the APOE ε system in producing the CAAD association
signal in this region, because one would expect the causal
polymorphism to achieve greater statistical significance
than, and in fact eliminate signal from, surrounding neu-
tral variation. Instead, our data are most consistent with a
causal polymorphism or collection of polymorphisms in
linkage disequilibrium with both rs2075650 and the
APOE ε system.
In summary, our data replicate the majority of associa-
tions reported between SNPs and HDL and LDL. Unbi-
ased or slightly negatively biased estimates of the
proportion of variance in HDL and LDL levels explained
by these SNPs are 3.9% and 3.3% respectively, consistent
with previous estimates[11]. The combined set of SNPs
currently available does not improve CAAD risk predic-
tion beyond what would be expected from their effects on
HDL and LDL levels, but the specific SNPs rs646776 and
rs2075650 are associated with CAAD risk, possibly due to
their effects on LDL particle number and buoyancy,
respectively.
Methods
Clear study participants
The Carotid Lesion Epidemiology And Risk (CLEAR)
Study is a Seattle-based study involving the University of
Washington (UW), Virginia Mason Medical Center (VM)
and the Veterans Affairs Puget Sound Health Care System
(VAPSHCS), focused on identifying predictors of CAAD,
CAAD progression, and atherosclerotic plaque instability
approved by the UW, VM, and VAPSHCS IRBs. All partic-
ipants gave written informed consent. Participant charac-
teristics are shown in Table 1. Only Caucasian males were
analyzed due to under-representation of women and
minorities in the cohort. Self reported ancestry was con-
firmed by STRUCTURE [35]. Individuals with total serum
cholesterol >400 mg/dL or coagulopathy were excluded.
Controls include 479 individuals with ≤15% carotid sten-
osis bilaterally as measured by duplex ultrasound. Indi-
viduals with vascular disease at other sites were excluded
from the set of controls. Cases include 353 individuals sta-
tus post carotid endarterectomy for symptomatic disease
or asymptomatic individuals with ≥80% internal carotid
stenosis either unilaterally or bilaterally. Individuals with
intermediate stenosis have 50% to 79% luminal narrow-
ing either unilaterally or bilaterally. Cases and controls
were matched on age distribution, with censoring occur-
ring at the time of diagnosis of vascular disease for cases
or at the time of the last blood draw for controls. Hyper-
tension was defined by treatment with antihypertensive
medications. Diabetes was defined as a hemoglobin
A1C≥6.5 or use of oral hypoglycemics or insulin.
Lipid phenotypes
Standard methods were used to determine total choles-
terol, triglycerides, and HDL in fasting whole plasma
using an Abbott Spectrum analyzer. LDL was calculated
unless triglycerides were ≥400 mg/dL, in which case it was
measured directly. HDL fractions 2 and 3 were deter-
mined by precipitating HDL2 from total HDL, measuring
HDL3 in the supernatant, and subtracting this from total
HDL to obtain HDL2. Apolipoprotein A-I, apolipoprotein
B, and lipoprotein(a) were measured as described by Mar-
covina et al [36], Zambon et al [37], and Marcovina et al
[38], respectively. LDL buoyancy was measured by the rel-
ative flotation rate Rf as described by Capell et al [22]. We
utilized lipid measurements prior to initiation of lipid
lowering therapy whenever possible. For 90 individuals
with two to three repeated lipid measurements we used
the mean of these measurements. Based on inspection of
the raw phenotype and residuals distributions, we
excluded 6 outlying individuals with HDL>100 mg/dL, 10
individuals with HDL2>25 mg/dL, 4 individuals with
HDL3>80, and 4 individuals with apo A-I>225 mg/dL. We
also excluded 4 outlying individuals with LDL>200 mg/
dL and 4 individuals with LDL fraction apolipoprotein
B>120 mg/dL. The positively skewed lipoprotein (a) dis-
tribution was log transformed.
Genotyping and SNPs
Genotypes were measured using the Illumina
HumanCVD Genotyping BeadChip using an Illumina
BeadStation Laboratory System platform[39,40]. Dupli-
cate genotyping for 34 individuals showed 99.7% consist-
ency in calls. The APOE ε2/ε3/ε4 polymorphism was
genotyped as previously described [41]. Additional SNPs
in the chromosome 1p13.3 and 19p13.2 regions were
genotyped using TaqMan Assays by Design on an Applied
Biosystems 7900HT System [42]. Using unphased refer-
ence genotypes from release 27 of the HapMap projectLipids in Health and Disease 2009, 8:52 http://www.lipidworld.com/content/8/1/52
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[43]. we performed imputation for untyped SNPs using
BIMBAM [44,45]. Although inaccurate genotype imputa-
tion is expected to cause false negatives rather than false
positives, to avoid spurious conclusions we sought to
determine which HapMap SNPs could be accurately
imputed relying on the SNPs genotyped in the CLEAR
study. We selected a random set of 10 individuals from
the HapMap CEU sample and set to missing those SNPs
not genotyped in the CLEAR study. We then imputed
these missing SNPs using the remaining SNPs that had
been genotyped in the CLEAR study. For each imputed
SNP we computed the correlation between the imputed
mean genotypes and the true genotypes for those HapMap
individuals in whom genotypes had been masked. We
repeated this procedure 20 times, selecting a different set
of 10 individuals for genotype masking each time, and we
report the imputation accuracy as the mean correlation
over these 20 iterations. Only SNPs with >90% imputa-
tion accuracy were included in downstream analyses.
Statistical analyses
All analyses were performed in R[46]. Unless otherwise
specified, tests for genetic association were performed
assuming an additive model with the homozygous geno-
types coded as 0 or 2 and the heterozygous genotype
coded as 1. Analyses of lipid phenotypes were performed
in cases, individuals with intermediate stenosis, and con-
trols using linear regression with censored age, body mass
index (BMI), hypertension, diabetes, and use of lipid low-
ering therapy as covariates. Current cigarette usage was
included as a covariate for analyses of HDL. Unless other-
wise specified analyses of CAAD were performed using
logistic regression with case status (≥80% stenosis) coded
as 1 and control status (≤15% stenosis) coded as 0 and
censored age, current cigarette usage, pack-years smoked,
BMI, hypertension, and diabetes as covariates. To account
for multiple testing we estimated false discovery rates
(FDR) using the Benjamini-Hochberg procedure[47].
Analysis of CAAD risk in the setting of lipid lowering 
therapy
Consistent with guidelines[18], cases with CAAD in the
CLEAR study are generally treated with lipid lowering
therapy to a target of LDL<100 mg/dL, whereas controls,
who are without CAAD, coronary artery disease, or risk
equivalents, are managed with a target LDL of <130 mg/
dL or <160 mg/dL. Thus, including HDL, LDL, or lipid
lowering therapy as covariates is problematic because it
leads to a model in which the dependent variable, CAAD
case control status, is causal for these independent varia-
bles. However, in order to study the effects of SNPs on
CAAD in the context of lipid risk factors, we attempted to
estimate "pre-therapy" HDL and LDL values for those
individuals on lipid lowering therapy. We based on these
values on the lipid altering effects of statins, the drug class
for 92% of all lipid draws when therapy was in use. For
HDL, we estimated that the post-therapy values were
2.1% to 9.6% higher than pre-therapy[48], and for LDL
30% to 63% lower than pre-therapy[48,49]. We also esti-
mated the percent change in HDL (13% increase) and
LDL (28% decrease) from 41 individuals in the CLEAR
study who had measurements both prior to and following
initiation of lipid lowering therapy.
Power to detect association between genetic risk scores 
and CAAD
We performed simulations to determine our power to
detect association between the genetic risk score and
CAAD, given the percent variation in HDL and LDL levels
explained by the genetic risk score and given the effect size
of dyslipidemia as a risk factor for CAAD. Using the esti-
mated "pre-therapy" HDL and LDL values described
above, we first permuted the observed genotypes so that
an additive score for the 16 HDL SNPs explained on aver-
age 3.9% of the variance in HDL levels and so that an
additive score for the 18 LDL SNPs explained on average
3.3% of the variance in LDL levels. We then combined the
HDL and LDL scores to form the overall genetic risk score.
Next we simulated CAAD status by sampling binomial
random variables with underlying probabilities given by
the fitted effects of a logistic regression model that
included "pre-therapy" HDL and LDL levels as well as all
other covariates. For the three different "pre-therapy"
HDL and LDL estimates described above, the odds ratios
for association with CAAD in this model ranged from
0.95 to 0.96 per mg/dL change in HDL and 1.010 to 1.011
per mg/dL change in LDL. Finally, we tested for associa-
tion between the simulated genetic risk score and simu-
lated CAAD status in the setting of the usual covariates
without HDL or LDL levels in the model. To estimate the
expected odds ratio for the genetic risk score and the
power, we performed 1000 such simulations for each of
the three different estimates of "pre-therapy" HDL and
LDL levels.
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